Glucoraphanin vegetable soup and blood extracellular vesicles.

Not Applicable

• Conditions: Inflammation; Oxidative stress; Dietary and Nutrition disorders; Diet and Nutrition - Other diet and nutrition disorders; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12623000747628
• Lead Sponsor: iggins Institute, The University of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-07-10
• Last Update Posted: 18 July 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

•Ethnicity: All
•Gender: Males and females
•Age: >55yr
•BMI:18.5-30 kg/m2
•Non-smokers
•Able and willing to attend all site visits

Exclusion Criteria

•Current illness or condition which in the view of the investigator and/or advising clinician at the Liggins Institute would affect the compliance or safety of the individual taking part.
•Gastrointestinal disorder that alters nutrient digestion and absorption (e.g., ulcerative colitis, Crohn’s disease, coeliac disease, an ileostomy or colostomy).
•Current use of medications which may interfere with normal digestive processes including proton pump inhibitors, laxatives, and antacids.
•Have used antibiotics within the previous one month or are currently on long-term antibiotics.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To examine changes in the composition and abundance of antioxidant proteins in the circulatory extracellular vesicle as a composite primary outcome- an exploratory outcome.<br><br>Plasma samples will be analyzed to characterise blood extracellular vesicles by ultracentrifugation, size exclusion chromatography, NTA NS300, transmission electron microscopy, BCA protein assay and western blot. ELISA/LC-MS will analyse the EVs' protein composition.<br>(randomized cross-over design)<br>[On 6 different occasions: <br>Treatment Visits (Randomly assigned) 2 & 5; at baseline and 30, 45, 60, 90, 120, 180, 240, 360 and 480 min<br> Interim Visits 3,4, 6 and 7: 24 hr and 48 hr respectively ]

Secondary Outcome Measures

Name	Time	Method
Changes in the plasma metabolites of sulforaphane metabolism- exploratory outcome<br><br>Plasma metabolites will be analyzed using LC-MS (randomized cross-over design)[On 6 different occasions:<br>Treatment Visits (Randomly assigned) 2 & 5; at baseline and 30, 45, 60, 90, 120, 180, 240, 360 and 480 min<br> Interim Visits 3,4, 6 and 7: 24 hr and 48 hr respectively ];Change in the abundance of miRNAs in extracellular vesicles-exploratory outcome<br>[At baseline and 30, 45, 60, 90, 120, 180, 240, 360 and 480 min and 24 hr and 48 hr respectively. ];Changes in the Urine metabolites of sulforaphane metabolism- exploratory outcome<br>Urine samples will be analyzed using LC-MS. Participants will be provided with a urine collection bottle to carry home for 24hr and then for a 24-48-hour visit after consumption of the soup.[At baseline and 0-2, 2-4, 4-6, 6-8hr, 8-24hr and 24-48h, respectively. <br> (randomized cross-over design)]